Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
April 13, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the...
March 07, 2022 16:30 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it...
December 08, 2021 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer

Dr. Zhang steps into the CSO role after spending more than five years at Ikena in research and development leadership Jeffrey Ecsedy, Ph.D., taking on newly created role as Chief Development...
November 12, 2021 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175

Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors Study evaluates IK-175 in urothelial carcinoma...
November 10, 2021 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update

IND for IK-930 accepted by FDA; Phase 1 clinical trial expected to initiate in early 2022 Progressing RAS pathway research programs with multiple development candidates expected in the next 18 months...
November 04, 2021 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Participate in November 2021 Virtual Investor Conferences

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced...
November 02, 2021 08:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930

BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, announced today...
October 07, 2021 09:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment

Meeting, taking place October 7-10, 2021, is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment...
October 01, 2021 08:15 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three...